Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 20Recurrence 5Leukemia, Myeloid, Acute 4Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Waldenstrom Macroglobulinemia 1Renal Insufficiency 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Hypergammaglobulinemia 1Hodgkin Disease 1Hematologic Diseases 1Disease 1Breast Neoplasms 1

Interventions

Cyclophosphamide 4Prednisone 3Lenalidomide 3fludarabine phosphate 2etoposide phosphate 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Stem Cell Transplantation 2Nivolumab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Doxorubicin 2Bortezomib 2Alemtuzumab 2tazemetostat 1sargramostim 1romidepsin 1poly ICLC 1plerixafor 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1pegaspargase 1liposomal doxorubicin 1forodesine 1fludarabine 1duvelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell × daratumumab × Clear all
NCT04251065 2025-03-28

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Fondazione Italiana Linfomi - ETS

Phase 2 Terminated
8 enrolled 17 charts
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡